
 
 
 
 
 
 
 
 
   
 An anti-annexin-V monoclonal antibody produced by a
hybridoma cell line which is selected from the group consisting of the
hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at
the International Depository Authority for the deposit of microorganisms,
said anti-annexin-V monoclonal antibody being cross-reactive with
annexin-V from the heart cells of one or more mammalian species. 
 
     
 A hybridoma cell line selected from the group consisting of the
hybridoma cell lines deposited as FERM BP-5284 and FERM BP-5286 at
the International Depository Authority for the deposit of microorganisms,
said hybridoma cell line having the ability to produce an anti-annexin-V
monoclonal antibody which has a binding specificity to an antigenic
determinant on annexin-V antigenic protein and which is capable of
cross-reacting with annexin-V from the heart of one or more mammalian
species. 
 
     
 A set of reagents for the detection of myocardial infarction and angina pectoris
which comprises:
   a first reagent containing a first anti-annexin-V monoclonal
antibody being produced by a hybridoma cell line selected from the
group consisting of the hybridoma cell lines deposited as FERM BP-5284
and FERM BP-5286 at the International Depository Authority for the
deposit of microorganisms;   a second reagent containing a second anti-annexin-V monoclonal
antibody being produced by the other hybridoma cell line selected from
said group, wherein the antibody of the second reagent is labeled;   wherein the antibodies of both reagents are cross-reactive with
annexin-V from human heart cells and the annexin-V antigen is annexin-V
from heat cells of one or more mammalian species.     
 
     
 The set of reagents for the detection of myocardial infarction and angina
pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody 
is anti-annexin-V monoclonal antibody produced by the hybridoma cell
line FERM BP-5284 and the labeled second anti-annexin-V monoclonal
antibody is produced by labeling the anti-annexin-V monoclonal antibody
produced by the hybridoma cell line FERM BP-5286. 
 
     
 The set of reagents for the detection of myocardial infarction and angina
pectoris of claim 3 in which the first anti-annexin-V monoclonal antibody
is anti-annexin-V monoclonal antibody produced by the hybridoma cell
line FERM BP-5286 and the labeled second anti-annexin-V monoclonal
antibody is produced by labeling the anti-annexin-V monoclonal antibody
produced by the hybridoma cell line FERM BP-5284. 
 
     
 A method of diagnosing myocardial infarction and angina
pectoris comprising the steps of :
   causing an antigen-antibody reaction of annexin-V in a sample
with a first anti-annexin-V monoclonal antibody to form an annexin-V
antigen-anti-annexin-V monoclonal antibody complex;   allowing the antigenic site of annexin-V of the formed annexin-V
antigen-anti-annexin-V monoclonal antibody complex to be bound with a
labeled second anti-annexin-V monoclonal antibody so as to form a
labeled form of said annexin-V antigen-anti-annexin-V monoclonal
antibody complex bound with the monoclonal antibody; and   quantitatively analyzing the labeled form of said complex to
perform said diagnoses, wherein the respective anti-annexin-V
antibodies are produced by a hybridoma cell line which is selected from the
group consisting of the hybridoma cell lines deposited as FERM BP-5284
and FERM BP-5286.     
 
     
 The method for diagnosing myocardial infarction and angina
pectoris of claim 6 in which the first anti-annexin-V monoclonal antibody
is anti-annexin-V monoclonal anti-body produced by the hybridoma cell
line FERM BP-5284. 
 
     
 The method for diagnosing myocardial infarction and angina
pectoris of claim 6 in which the first anti-annexin-V monoclonal antibody
is anti-annexin-V monoclonal antibody produced by the hybridoma cell
line FERM BP-5286. 
 
     
 The method for diagnosing myocardial infarction and angina
pectoris of claim 6 in which the labeled second anti-annexin-V
monoclonal antibody produced by the hybridoma cell line FERM BP-5284. 
 
     
 The method for diagnosing myocardial infarction angina
pectoris of claim 6 in which the labeled second anti-annexin- monoclonal
antibody is anti-annexin-V monoclonal antibody produced by the
hybridoma cell line FERM BP-5286. 
 
     
 A method for analyzing annexin-V in human cardiac muscle or
in a sample which comprises causing an antigen-antibody reaction of
human annexin-V in the human cardiac muscle or the sample with an
anti-annexin-V monoclonal antibody produced by a hybridoma cell line
selected from the group consisting of the hybridoma cell lines deposited
as FERM BP-5284 and FERM BP-5286 at the International Depository
Authority for the deposit of microorganisms, to form an annexin-V
antigen-anti-annexin-V monoclonal antibody complex and quantitatively 
analyzing the formed annexin-V antigen-anti-annexin-V monoclonal
antibody complex. 
 
     
 A method for analyzing annexin-V in a sample which
comprises the steps of:
   causing an antigen-antibody reaction of human annexin-V in the
sample with a first anti-annexin-V monoclonal antibody produced by a
hybridoma cell line selected from the group consisting of the hybridoma
cell lines deposited as FERM BP-5284 and FERM BP-5286 at the
International Depository Authority for the deposit of microorganisms to
form an annexin-V antigen-anti-annexin-V monoclonal antibody complex,   allowing the antigenic site of human annexin-V of the formed
annexin-V antigen-anti-annexin-V monoclonal antibody complex to be
bound with a labeled second anti-annexin-V monoclonal antibody, so as
to form a labeled form of said annexin-V antigen-anti-annexin-V
monoclonal antibody complex bound with the labeled second anti-annexin-V
monoclonal antibody, and   quantitatively analyzing the labeled form of the complex, wherein
said labeled second anti-annexin-V monoclonal antibody is produced by
labeling second anti-annexin-V monoclonal antibody being different from
the first anti-annexin-V monoclonal antibody and produced by a
hybridoma cell line which is selected from the group consisting of the
hybridoma cell line deposited as FERM BP-5284 and FERM BP-5286 at
the International Depository Authority for the deposit of microorganisms.     
 
     
 The method of claim 12 in which the first anti-annexin-V
monoclonal antibody is one produced by the hybridoma cell line FERM
BP-5284 and has a binding specificity for an antigenic determinant on
human annexin-V antigenic protein. 
 
     
 The method of claim 12 in which the first anti-annexin-V
monoclonal antibody is one produced by the hybridoma cell line FERM
BP-5286 and has a binding specificity for an antigenic determinant on
human annexin-V antigenic protein.  
 
     
 The method of claim 12 in which the labeled second anti-annexin-V
monoclonal antibody is produced by labeling the anti-annexin-V
monoclonal antibody produced by hybridoma cell line FERM BP-5284
and has a binding specificity for an antigenic determinant on human
annexin-V antigenic protein. 
 
     
 The method of claim 12 in which the labeled second anti-annexin-V
monoclonal antibody is produced by labeling the anti-annexin-V
monoclonal. antibody produced by hybridoma cell line FERM BP-5286
at and has a binding specificity for an antigenic determinant on human
annexin-V antigenic protein. 
 
   
 
 
 
 
 
 
 
 
